GPR101 mediates the pro-resolving actions of RvD5\textsubscript{n-3} DPA in arthritis and infections

Magdalena B. Flak, …, Francesco Palmas, Jesmond Dalli

*J Clin Invest.* 2020;130(1):359-373. https://doi.org/10.1172/JCI131609.

N-3 docosapentaenoic acid–derived resolvin D5 (RvD5\textsubscript{n-3} DPA) is diurnally regulated in peripheral blood and exerts tissue-protective actions during inflammatory arthritis. Here, using an orphan GPCR screening approach coupled with functional readouts, we investigated the receptor(s) involved in mediating the leukocyte-directed actions of RvD5\textsubscript{n-3} DPA and identified GPR101 as the top candidate. RvD5\textsubscript{n-3} DPA bound to GPR101 with high selectivity and stereospecificity, as demonstrated by a calculated $K_D$ of approximately 6.9 nM. In macrophages, $GPR101$ knockdown limited the ability of RvD5\textsubscript{n-3} DPA to upregulate cyclic adenosine monophosphate, phagocytosis of bacteria, and efferocytosis. Inhibition of this receptor in mouse and human leukocytes abrogated the pro-resolving actions of RvD5\textsubscript{n-3} DPA, including the regulation of bacterial phagocytosis in neutrophils. Knockdown of the receptor in vivo reversed the protective actions of RvD5\textsubscript{n-3} DPA in limiting joint and gut inflammation during inflammatory arthritis. Administration of RvD5\textsubscript{n-3} DPA during *E. coli*–initiated inflammation regulated neutrophil trafficking to the site of inflammation, increased bacterial phagocytosis by neutrophils and macrophages, and accelerated the resolution of infectious inflammation. These in vivo protective actions of RvD5\textsubscript{n-3} DPA were limited when $Gpr101$ was knocked down. Together, our findings demonstrate a fundamental role for GPR101 in mediating the leukocyte-directed actions of RvD5\textsubscript{n-3} DPA.

Find the latest version:

https://jci.me/131609/pdf
GPR101 mediates the pro-resolving actions of RvD5 \textsubscript{n-3 DPA} in arthritis and infections

Magdalena B. Flak, 1 Duco S. Koenis, 1 Agua Sobrino, 1 James Smith, 1 Kimberly Pistorius, 1 Francesco Palmas, 1 and Jesmond Dalli\textsuperscript{1,2}

1William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, and 2Centre for Inflammation and Therapeutic Innovation, Queen Mary University of London, Charterhouse Square, London, United Kingdom.

**Introduction**

Development of the inflammatory response was a fundamental step in the evolution of multicellular organisms, given that this mechanism is vital in warding off invading pathogens and in coordinating reparative and regenerative mechanisms (1, 2). Leukocytes play a central role in the clearance of pathogens, in which, for example, neutrophils and macrophages are tasked with the uptake and killing of bacteria (3, 4). These cells are also important in coordinating the termination of acute inflammation as well as initiating tissue repair and regeneration (4–6). Central to the protective actions exerted by leukocytes is a novel genus of mediators termed specialized pro-resolving mediators (SPMs) (4, 7, 8). These autacoids are produced through the enzymatic conversion of essential fatty acids, which yields molecules with a defined stereochemistry and potent biological properties (4, 7, 8).

Recent studies demonstrate that in addition to arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid (DHA), n-3 docosapentaenoic acid (n-3 DPA) is also a substrate for conversion to novel, structurally distinct bioactive mediators (SPMs) (4, 7, 8). These autacoids are produced through the enzymatic conversion of essential fatty acids, which yields molecules with a defined stereochemistry and potent biological properties (4, 7, 8).

N-3 docosapentaenoic acid–derived resolvin DS (RvD5\textsubscript{n-3 DPA}) is diurnally regulated in peripheral blood and exerts tissue-protective actions during inflammatory arthritis. Here, using an orphan GPCR screening approach coupled with functional readouts, we investigated the receptor(s) involved in mediating the leukocyte-directed actions of RvD5\textsubscript{n-3 DPA} and identified GPR101 as the top candidate. RvD5\textsubscript{n-3 DPA} bound to GPR101 with high selectivity and stereospecificity, as demonstrated by a calculated \(K_D\) of approximately 6.9 nM. In macrophages, GPR101 knockdown limited the ability of RvD5\textsubscript{n-3 DPA} to upregulate cyclic adenosine monophosphate, phagocytosis of bacteria, and efferocytosis. Inhibition of this receptor in mouse and human leukocytes abrogated the pro-resolving actions of RvD5\textsubscript{n-3 DPA}, including the regulation of bacterial phagocytosis in neutrophils. Knockdown of the receptor in vivo reversed the protective actions of RvD5\textsubscript{n-3 DPA} in limiting joint and gut inflammation during inflammatory arthritis. Administration of RvD5\textsubscript{n-3 DPA} during \(E. coli\)–initiated inflammation regulated neutrophil trafficking to the site of inflammation, increased bacterial phagocytosis by neutrophils and macrophages, and accelerated the resolution of infectious inflammation. These in vivo protective actions of RvD5\textsubscript{n-3 DPA} were limited when \(Gpr101\) was knocked down.

Together, our findings demonstrate a fundamental role for GPR101 in mediating the leukocyte-directed actions of RvD5\textsubscript{n-3 DPA}.

**Authorship note:** DSK and AS share second authorship.

**Copyright:** © 2020, Flak et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

**Conflict of Interest:** The authors have declared that no conflict of interest exists.

**Submitted:** July 8, 2019; **Accepted:** October 8, 2019; **Published:** December 3, 2019.

**Reference Information:** J Clin Invest. 2020;130(1):359–373. https://doi.org/10.1172/JCI131609.
(16, 17) and RvD2 activating GPR18 (18). Of note, the identity of the receptor mediating the biological actions of RvD5-n-3 DPA is not known.

In the present study, we used an integrated approach to establish the identity of the GPCR that mediates the pro-resolving actions of RvD5-n-3 DPA on leukocytes. Results from these experiments identified GPR101 as a candidate receptor for RvD5-n-3 DPA. Flow cytometric analysis demonstrated that GPR101 was expressed on both human and mouse peripheral blood leukocytes. Using radioactively labeled RvD5-n-3 DPA, we observed specific binding of this mediator to GPR101 with an affinity that was within its bioactive range. Knockdown of Gpr101 in mice led to an abrogation of the protective actions of RvD5-n-3 DPA in vivo by limiting its ability to regulate inflammatory arthritis and infectious inflammation.

**Results**

**Identification of candidate receptors for RvD5-n-3 DPA.** In order to establish whether the biological actions of RvD5-n-3 DPA were mediated by a GPCR, we screened a panel of orphan GPCRs to determine whether RvD5-n-3 DPA showed agonistic activity toward these receptors, using 10 nM RvD5-n-3 DPA and assessing increases in luminescence as a readout for receptor activation. Here, we found that the strongest agonistic signals elicited by this pro-resolving mediator were with GPR101, GPR12, and GPR84 (Figure 1A), with values approximately 15%–20% above the control value. Given that RvD5-n-3 DPA regulates the biological actions of monocyte-derived macrophages and peripheral blood leukocytes (9, 10), we next investigated the expression of these 3 receptors on circulating human neutrophils and monocytes and identified all 3 receptors (Figure 1B). Moreover, human monocyte-derived macrophages also expressed all 3 receptors on their cell surface (Figure 1C).

**RvD5-n-3 DPA stereospecifically activates GPR101.** To establish the role of these receptors in mediating the biological actions of RvD5-n-3 DPA, we evaluated the ability of this ligand to activate each of these 3 receptors using a β-arrestin-based ligand receptor interaction screening system, which enabled the construction of full dose-response curves (19). In these settings, RvD5-n-3 DPA increased chemiluminescence in a concentration-dependent manner in cells overexpressing GPR101, with a calculated EC₅₀ of 4.6 × 10⁻¹² M (Figure 2A). Of note, this increase in chemiluminescence was not observed in cells expressing either GPR12 or GPR84 (Figure 2A). Using the β-arrestin system, we also tested whether RvD5-n-3 DPA activates the pro-resolving receptors GPR32 (also known as DRV1) and GPR18 (also known as DRV2). Here, we found that RvD5-n-3 DPA displayed an affinity for GPR32/DRV1 comparable to that observed with RvD1, with an EC₅₀ of approximately 1.4 × 10⁻¹¹ M and approximately 1.5 × 10⁻¹² M, respectively. Of note, RvD5-n-3 DPA did not appear to activate GPR18/DRV2 at biologically relevant concentrations (Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI13609DS1).

Given that GPCR activation leads to changes in both cell shape and size (20), we next used an impedance-based assay to further evaluate the interactions between RvD5-n-3 DPA and GPR101. We found that incubation of RvD5-n-3 DPA with GPR101-expressing CHO cells led to changes in impedance, an observation that was markedly reversed when these cells were preincubated with an anti-GPR101 antibody (Figure 2B).

We next investigated the stereospecificity of the interaction between RvD5-n-3 DPA and GPR101, assessing the capacity of related n-3 DPA-derived SPMs to activate this receptor. Incubation of GPR101-expressing cells with either RvD1-n-3 DPA or PD1-n-3 DPA (10R,17S-dihydroxy-7Z,11E,13E,15Z,19Z-docosapentaenoic acid) did not elicit notable increases in chemiluminescent signals (Figure 2C), indicating a degree of selectivity for RvD5-n-3 DPA. We made similar observations when assessing impedance changes, in which addition of RvD1-n-3 DPA or PD1-n-3 DPA to GPR101-expressing cells only elicited marginal changes in impedance (Figure 2D). To investigate the stereospecific nature of these receptor-ligand interactions, we next tested the ability of isopropyl-(7S,8E,15E,17S,19Z)-7,17-dihydroxydocosa-8,15,19-trien-10,13-diyanoate (DA-RvD5-n-3 DPA), an analog of RvD5-n-3 DPA, to elicit changes in impedance. We found that substituting the double bond in the middle portion of the analog for triple bond, which would increase the rigidity of the molecule, led to a significant decrease in the ability of the molecule to activate the receptor (Figure 3, A and B). We further evaluated the stereospecific nature of the interaction between RvD5-n-3 DPA and GPR101 by assessing whether the DHA-derived RvD5 (7S,17S-dihydroxy-4Z,8E,10Z,13Z,15E,19Z-docosahexaenoic acid), which differs from the n-3 DPA congener by having an extra double bond on carbons 4 and 5, activates GPR101 to a similar degree. Using both impedance assays and the β-arrestin system, we found that RvD5 activated GPR101 to an extent similar to that seen with RvD5-n-3 DPA, with a calculated EC₅₀ of approximately 6.4 × 10⁻¹⁴ M and approximately 9.7 × 10⁻¹⁵ M, respectively (Figure 3, C and D).

We next tested the role of G proteins in mediating the signals generated by RvD5-n-3 DPA via the activation of GPR101. For this purpose, we incubated cells with either cholera toxin (CTX) (Gₛ-like protein inhibitor) or pertussis toxin (PTX) (Gₛ-like protein inhibitor) prior to addition of RvD5-n-3 DPA. Incubation of cells with CTX, but not PTX, markedly inhibited the changes in impedance elicited by RvD5-n-3 DPA (Figure 3E). These results suggest that activation of GPR101 by RvD5-n-3 DPA promotes the recruitment of Gₛ-like proteins. Given that cAMP is the downstream messenger of Gₛ, we next investigated whether RvD5-n-3 DPA upregulates cAMP in human monocyte-derived macrophages using an siRNA approach. Incubation of these cells with RvD5-n-3 DPA led to an increase in cAMP concentrations (168 ± 56 pmol vs. 290 ± 98 pmol per 0.4 × 10⁶ cells), an increase that was absent in cells transfected with an siRNA against GPR101 (Figure 3F).

**Binding of ⁴⁺H-RvD₅-n-3 DPA to GPR101.** Next, we determined the affinity of the ligand–receptor interaction. For this purpose, we prepared tritium-labeled RvD5-n-3 DPA by catalytic tritiation with [10, 11, 13, 14⁻³H]-RvD5-n-3 DPA, as well as matching UV chromophores with an UV absorbance maximum in ethanol (λₑₓ max (ETOH)) of 245 nm (Figure 4A). Furthermore, quantification of radioactivity demonstrated that approximately 98% of the activity was associated with [10, 11, 13, 14⁻³H]-RvD5-n-3 DPA.
Figure 1. RvD5_5,10_n relevant receptor candidates are expressed on human leukocytes. (A) Activation of orphan receptors by RvD5_5,10_n (10 nM). Results represent the percentage increase in luminescence signal over vehicle control. (B and C) Expression of the top 3 candidate receptors on human (B) peripheral blood leukocytes and (C) macrophages. Results are representative of 4 donors. FSC, forward scatter; SSC, side scatter.
given that the peak in activity coincided with the eluting of the molecule (Figure 4B). We next conducted saturation binding studies to establish the $K_d$ for binding of RvD$_{5n-3}$ DPA to GPR101. These experiments yielded a calculated $K_d$ of approximately 6.9 nM (Figure 4C). To determine the specificity of the RvD$_{5n-3}$ DPA–GPR101 interaction, we next sought to establish the IC$_{50}$ of the interaction. We found that RvD$_{5n-3}$ DPA and PD$_{1n-3}$ DPA competed for GPR101 binding, with an IC$_{50}$ of approximately 9.3 nM (Figure 4D). Together, these results demonstrate that the affinity of RvD$_{5n-3}$ DPA for GPR101 was within the bioactive range for this mediator (9, 10).

**GPR101 mediates the regulatory actions of RvD$_{5n-3}$ DPA on macrophages.** In order to test the functional role of GPR101 in mediating the pro-resolving actions of RvD$_{5n-3}$ DPA in human monocyte-derived macrophages, we next knocked down the expression of this receptor using siRNA. Given the central role of macrophages in promoting the resolution of bacterial infections via the uptake and killing of pathogens in a process termed phagocytosis (4, 7, 18), we next investigated whether RvD$_{5n-3}$ DPA regulates phagocytosis of bacterial particles in a GPR101-dependent manner. For this purpose, we used pHrodo Green–conjugated *Staphylococcus aureus* (S. aureus) bioparticles that become increasingly fluorescent as pH decreases, thus providing a readout of phagocytic uptake and subsequent phagolysosomal degradation of ingested material. Incubation of scrambled control siRNA–transfected macrophages with RvD$_{5n-3}$ DPA led to a dose-dependent increase in phagocytosis of pHrodo Red–labeled apoptotic cells. Meanwhile, transfection of macrophages with an siRNA against GPR101 limited the ability of RvD$_{5n-3}$ DPA to upregulate phagocytosis in a similar manner (Figure 5, A–C).

Next, we tested the ability of these macrophages to take up neutrophils and monocytes. Since RvD$_{5n-3}$ DPA regulates the biological actions of neutrophils (9, 10, 23) and GPR101 is expressed on neutrophils (9, 10, 23), we complemented the results produced with human monocyte–derived macrophages by determining the neutrophil-directed actions of RvD$_{5n-3}$ DPA. Incubation of RvD$_{5n-3}$ DPA with human neutrophils led to a significant and dose-dependent reduction in both the rate of neutrophil migration toward leukotriene B$_4$ (LTB$_4$) and the total number of cells migrated (Figure 6, A–C). In addition, RvD$_{5n-3}$ DPA also reduced the number of cells that transmigrated through an activated endothelial cell monolayer under flow conditions (Figure 6D). Incubation of neutrophils to an antibody targeting GPR101 reversed the biological actions of RvD$_{5n-3}$ DPA.
GPR101 mediates the antiarthritic actions of RvD5n-3 DPA. RvD5n-3 DPA displays potent antiarthritic actions that regulate both neutrophil and macrophage responses in inflammatory arthritis (11). Thus, we next investigated the role of GPR101 in mediating these protective actions. For this purpose, we treated mice with either an siRNA targeting mouse Gpr101 to knock down the expression of this receptor in vivo, or a control sequence. We then challenged the mice with arthritogenic serum from K/BxN mice, which initiates a polyarthritic disease driven by both monocytes and neutrophils (24). Assessment of clinical scores revealed that treatment of mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant reduction in clinical scores when compared with vehicle-treated mice (5.5 ± 1.8 in RvD5n-3 DPA-treated mice vs. 9.0 ± 0.5 in mice given vehicle), increasing both neutrophil chemotaxis and transmigration (Figure 6, A–D).

Since neutrophils are pivotal for the clearance of bacterial infections (3, 4), we next tested whether RvD5n-3 DPA, via GPR101, increases the ability of these cells to take up bacteria. Flow cytometric assessment of peripheral blood neutrophils and monocytes demonstrated that these cells expressed the murine ortholog of human GPR101 (Supplemental Figure 2). Incubation of whole blood from mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant increase in bacterial phagocytosis by both neutrophils (643 ± 96 vs. 1886 ± 154 MFI units) and monocytes (1280 ± 97 vs. 3418 ± 208 MFI units). These actions were reversed when the mediator was added to peripheral blood collected from mice transfected with siRNA against Gpr101 that reduced the expression of the receptor on peripheral blood leukocytes (Figure 6, E and F, and Supplemental Figure 3). Together, these findings establish a role for GPR101 in mediating the biological actions of RvD5n-3 DPA on neutrophils and monocytes.

**GPR101 mediates the antiarthritic actions of RvD5n-3 DPA.** RvD5n-3 DPA displays potent antiarthritic actions that regulate both neutrophil and macrophage responses in inflammatory arthritis (11). Thus, we next investigated the role of GPR101 in mediating these protective actions. For this purpose, we treated mice with either an siRNA targeting mouse Gpr101 to knock down the expression of this receptor in vivo, or a control sequence. We then challenged the mice with arthritogenic serum from K/BxN mice, which initiates a polyarthritic disease driven by both monocytes and neutrophils (24). Assessment of clinical scores revealed that treatment of mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant reduction in clinical scores when compared with vehicle-treated mice (5.5 ± 1.8 in RvD5n-3 DPA-treated mice vs. 9.0 ± 0.5 in mice given vehicle), increasing both neutrophil chemotaxis and transmigration (Figure 6, A–D).

Since neutrophils are pivotal for the clearance of bacterial infections (3, 4), we next tested whether RvD5n-3 DPA, via GPR101, increases the ability of these cells to take up bacteria. Flow cytometric assessment of peripheral blood neutrophils and monocytes demonstrated that these cells expressed the murine ortholog of human GPR101 (Supplemental Figure 2). Incubation of whole blood from mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant increase in bacterial phagocytosis by both neutrophils (643 ± 96 vs. 1886 ± 154 MFI units) and monocytes (1280 ± 97 vs. 3418 ± 208 MFI units). These actions were reversed when the mediator was added to peripheral blood collected from mice transfected with siRNA against Gpr101 that reduced the expression of the receptor on peripheral blood leukocytes (Figure 6, E and F, and Supplemental Figure 3). Together, these findings establish a role for GPR101 in mediating the biological actions of RvD5n-3 DPA on neutrophils and monocytes.

**GPR101 mediates the antiarthritic actions of RvD5n-3 DPA.** RvD5n-3 DPA displays potent antiarthritic actions that regulate both neutrophil and macrophage responses in inflammatory arthritis (11). Thus, we next investigated the role of GPR101 in mediating these protective actions. For this purpose, we treated mice with either an siRNA targeting mouse Gpr101 to knock down the expression of this receptor in vivo, or a control sequence. We then challenged the mice with arthritogenic serum from K/BxN mice, which initiates a polyarthritic disease driven by both monocytes and neutrophils (24). Assessment of clinical scores revealed that treatment of mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant reduction in clinical scores when compared with vehicle-treated mice (5.5 ± 1.8 in RvD5n-3 DPA-treated mice vs. 9.0 ± 0.5 in mice given vehicle), increasing both neutrophil chemotaxis and transmigration (Figure 6, A–D).

Since neutrophils are pivotal for the clearance of bacterial infections (3, 4), we next tested whether RvD5n-3 DPA, via GPR101, increases the ability of these cells to take up bacteria. Flow cytometric assessment of peripheral blood neutrophils and monocytes demonstrated that these cells expressed the murine ortholog of human GPR101 (Supplemental Figure 2). Incubation of whole blood from mice transfected with a control siRNA sequence with RvD5n-3 DPA led to a significant increase in bacterial phagocytosis by both neutrophils (643 ± 96 vs. 1886 ± 154 MFI units) and monocytes (1280 ± 97 vs. 3418 ± 208 MFI units). These actions were reversed when the mediator was added to peripheral blood collected from mice transfected with siRNA against Gpr101 that reduced the expression of the receptor on peripheral blood leukocytes (Figure 6, E and F, and Supplemental Figure 3). Together, these findings establish a role for GPR101 in mediating the biological actions of RvD5n-3 DPA on neutrophils and monocytes.
whereas in mice transfected with an siRNA against Gpr101, this antiarthritic activity of RvD5 n-3 DPA was lost (9.5 ± 0.3 in RvD5 n-3 DPA–treated mice vs. 10.5 ± 1.7 in mice given vehicle) (Figure 7, A and B). Transfection of mice with an siRNA against Gpr101 diminished the ability of this mediator to protect against weight loss (a marker of disease severity), limit joint edema, and reduce joint concentrations of the inflammation-initiating prostaglandins and LTB4 (Figure 7, C–F).

We recently found that inflammatory arthritis disrupts gut barrier function, which promotes joint inflammation (11). RvDS n-3 DPA administration reduced intestinal inflammation and eicosanoid concentrations and upregulated intestinal proresolving mediator levels (11). Therefore, in this study, we assessed whether GPR101 was central to these modulatory properties of RvD5 n-3 DPA. Lipid mediator profiling of intestinal tissues demonstrated that in mice administered a control siRNA sequence, RvDS n-3 DPA reduced the concentrations of the inflammatory eicosanoids, including PGD2 (193.4 ± 38.9 in vehicle-treated mice vs. 95.0 ± 15.7 pg/50 mg tissue) and PGE2 (376.3 ± 58.3 in vehicle-treated mice vs. 177.8 ± 16.9 pg/50 mg tissue), and increased the concentrations of select SPMs, namely RvD4 (0.6 ± 0.24 in vehicle-treated mice vs. 2.7 ± 0.3 pg/50 mg tissue).

Figure 4. Specific binding of [3H]-RvD5 n-3 DPA to human GPR101. (A and B) Characterization of [10, 11, 13, 14 3H]-RvD5 n-3 DPA ([3H]-RvD5 n-3 DPA). (A) RP-UV-HPLC chromatogram for RvD5 n-3 DPA and [3H]-RvD5 n-3 DPA. (B) RP-UV-HPLC chromatogram of [3H]-RvD5 n-3 DPA and online radioactivity monitoring. (C) GPR101-overexpressing CHO cells (0.5 × 10^6 cells in 100 μL) were incubated with [3H]-RvD5 n-3 DPA at the indicated concentrations in the presence or absence of 10 μM RvD5 n-3 DPA (60 minutes at 4°C). Cell incubations were transferred to a vacuum manifold, unbound radioligand was removed, and activity was measured. Results represent the mean ± SEM (n = 4 from 2 distinct experiments). Inset shows a Scatchard plot. (D) To assess competition binding, GPR101-expressing CHO cells (0.5 × 10^6 cells in 100 μL) were incubated with 3 nM [3H]-RvD5 n-3 DPA in the presence or absence of increasing concentrations of RvD5 n-3 DPA for 60 minutes at 4°C.
sue) and 17R-RvD1 (0.0 ± 0.0 in vehicle-treated mice vs. 0.21 ± 0.05 pg/50 mg tissue). Of note, these protective actions were diminished in mice transfected with the siRNA against Gpr101 prior to RvD5 n-3 DPA administration (Supplemental Figure 4).

RvD5 n-3 DPA accelerates the resolution of bacterial infections via GPR101. Having established that RvD5 n-3 DPA increased the ability of monocytes, macrophages, and neutrophils to take up bacteria, we next questioned whether this mediator was produced during bacterial infections and whether its production was temporally regulated during self-limited infections. For this purpose, we inoculated mice with E. coli and assessed the temporal production of RvD5 n-3 DPA using lipid mediator profiling. This analysis demonstrated that RvD5 n-3 DPA was produced during bacterial infections, with its production reaching a maximum at the 12-hour interval and remaining sustained into the resolution phase of the inflammatory response (Figure 8A). We next tested whether the protective actions of RvD5 n-3 DPA in promoting bacterial clearance as observed in vitro were retained in vivo and examined the role of GPR101 in mediating the observed regulatory actions. In mice given a control siRNA sequence, administra-
trophils recruited to the peritoneum (5.6 ± 0.9 × 10⁶ in vehicle-treated mice vs. 2.7 ± 0.7 × 10⁶ cells per mouse in RvD5₃ DPA–treated mice) (Figure 8C); a significant upregulation in the ability of exudate neutrophils (1400 ± 118 MFI units in vehicle-treated mice vs. 1873 ± 150 MFI units in RvD5₃ DPA–treated mice) and macrophages (3195 ± 94.7 MFI units in vehicle-treated mice vs. 3660 ± 129 MFI units in RvD5₃ DPA–treated mice) to adhere to cultured endothelial cells (Figure 8D). This reduction in the resolution interval was linked with a significant reduction in the number of neutrophils and macrophages in the peritoneal cavity (Figure 8E and F).

Figure 6. GPR101 mediates the protective actions of RvD5₃ DPA on neutrophils and monocytes. (A-C) Human neutrophils were incubated with anti-GPR101 antibody or an isotype control antibody (15 minutes at room temperature) and then with RvD5₃ DPA at the indicated concentrations or with vehicle (PBS containing 0.1% ethanol), and chemotaxis toward LTB₄ (10 nM) was assessed using the xCELLigence DP system. (A) Representative traces, (B) neutrophil chemotactic rate calculated from the slope of the curve, and (C) neutrophil chemotaxis calculated from the AUC of the traces shown in A. *P < 0.05 versus the indicated control group; Kruskal–Wallis test with Dunn’s post hoc multiple comparisons test. (D) Neutrophils were isolated and incubated as detailed above, and neutrophil–endothelial cell interactions were assessed after perfusing (0.1 Pa) neutrophils over an activated endothelial cell monolayer. Results represent the mean ± SEM (n = 4 donors from 3–4 distinct experiments). *P < 0.05 and ***P < 0.001 versus the indicated control group; 2-way ANOVA with Sidak’s post hoc test. (E and F) Mice were administered 9 µg siRNA against mouse Gpr101 or a scrambled control sequence. After 72 hours, blood was collected and cells incubated with RvD5₃ DPA (10 nM) or vehicle (20 minutes at 37°C) and then with 5 × 10⁷ CFU fluorescently labeled bacteria (30 minutes at 37°C), and phagocytosis in (E) neutrophils and (F) monocytes was assessed by flow cytometry. Results represent the mean ± SEM (n = 4 per group from 2 distinct experiments). **P < 0.01 versus the indicated control group; Kruskal–Wallis test with Dunn’s post hoc multiple comparisons test.
3965 ± 292 MFI units in RvD5_n-3 DPA–treated mice) to take up bacteria (Figure 8, D and E); and macrophage efferocytosis (Figure 8F). In these exudates, we also found a significant reduction in PGD2, PGE2, and the LTB4 metabolome, which encompasses the neutrophil chemoattractant LTB4 (Supplemental Figure 5).

Since macrophages are central players in both the termination and propagation of acute inflammation (4, 7, 18), we next investigated whether RvD5_n-3 DPA regulates exudate macrophage phenotype during infectious inflammation. In exudate macrophages from mice given RvD5_n-3 DPA and a control siRNA, we observed a decrease in the expression of MHC class II molecules (4863 ± 542 MFI units vs. 9136 ± 1536 MFI units in RvD5_n-3 DPA–treated mice vs. vehicle-treated mice). We observed an increase in the expression of the fractalkine receptor CX3CR1 (4010 ± 198 MFI units vs. 3160 ± 148 MFI units in RvD5_n-3 DPA–treated mice vs. vehicle-treated mice); the lipid mediator biosynthetic enzyme COX-2 (994 ± 70 MFI units vs. 1317 ± 106 MFI units in RvD5_n-3 DPA–treated mice vs. vehicle-treated mice); and the IL-10R (195 ± 35 MFI units vs. 88 ± 20 MFI units in RvD5_n-3 DPA–treated mice vs. vehicle-treated mice) (Figure 8G and Supplemental Figure 6), markers associated with a homeostatic and resolution macrophage phenotype (25, 26). Of note, transfection of mice with an siRNA against mouse Gpr101, which led to a reduction in neutrophil and macrophage receptor expression (Supplemental Figure 7), abolished the protective actions of RvD5_n-3 DPA on both of these cell types (Figure 8, A–G, and Supplemental Figure 7). Together, these findings demonstrate that RvD5_n-3 DPA activates host innate immune responses to promote the termination of infectious inflammation, actions that are mediated by GPR101.

Discussion
In the present study, using a screening approach, we identified GPR101 as a receptor for RvD5_n-3 DPA. We found that RvD5_n-3 DPA bound and activated GPR101 at a concentration that was com-
GPR101 is an X-linked receptor expressed on chromosome Xq26.3, the longer arm of the X chromosome. The GPR101 gene encodes a 508-aa deduced protein that shares approximately 30% sequence homology in the transmembrane regions with the \( \alpha \)-1A-adrenergic receptor and the serotonin 5HT1A receptor (https://www.omim.org/entry/300393#1). In human brain tissues, two GPR101 transcript variants have been identified, mensurate with its biological actions. Inhibition of GPR101 using anti-GPR101 antibodies and siRNA demonstrated a role for this receptor in mediating the immunoregulatory actions of RvD5\( \alpha \)-DPA in both human and mouse leukocytes. Knockdown of Gpr101 in vivo reversed the joint protective actions of RvD5\( \alpha \)-DPA during inflammatory arthritis and the pro-resolving actions of this mediator during bacterial infections.

GPR101 is an X-linked receptor expressed on chromosome Xq26.3, the longer arm of the X chromosome. The GPR101 gene encodes a 508-aa deduced protein that shares approximately 30% sequence homology in the transmembrane regions with the \( \alpha \)-1A-adrenergic receptor and the serotonin 5HT1A receptor (https://www.omim.org/entry/300393#1). In human brain tissues, two GPR101 transcript variants have been identified,
one of 9.5 kb and the second of 4.2 kb, whereas in mouse brain, a 5.5-kb transcript was identified. The human GPR101 protein shares approximately 71% identity with the deduced mouse protein, which is predicted to be 511 aa in size. In the present study, we demonstrate that this receptor was expressed on human and mouse neutrophils, monocytes, and macrophages (Figure 1 and Supplemental Figures 2, 3, and 7). In humans, several mutations have been identified for this receptor that include the E308D mutation, which was identified in tumour DNA (27). A second mutation, the substitution of D366E, was identified in a patient with sporadic acromegaly (28). However, the functional impact of these mutations is not well characterized, given that the endogenous ligand(s) for this receptor were not known.

Pro-resolving mediators exert potent actions in the regulation of innate immune responses. These biological actions are mediated via activation of select GPCRs, to which these molecules bind with high stereospecificity and affinity (14–18). In the present study, using radiolabeled RvD5 n-3 DPA, we found that this mediator bound to GPR101 with a Kᵦ of approximately 6.9 nM, which is comparable to its bioactive concentration range. We also found that RvD5 n-3 DPA, at concentrations as low as 0.1–10 nM was able to activate the receptor. This ability to activate intracellular signaling was found to be stereospecific, since neither RvD1 n-3 DPA nor PD1 n-3 DPA elicited marked changes in luminescence or impedance in GPR101-transfected CHO cells. Furthermore, subtle changes to the chemical backbone such as the substitution of the double bond at C10 and C13 for triple bond, which increases the rigidity of the molecule, also led to a significant (P < 0.5) decrease in its ability to activate the receptor.

Flow cytometric analysis revealed that GPR101 was expressed on both human and mouse neutrophils, monocytes, and macrophages. Leukocytes are involved in the initiation and termination of both sterile and inflammatory responses, with neutrophils, monocytes, and macrophages being the first responders (1, 2, 6, 7, 9, 18). SPMs, including RvD5 n-3 DPA, have leukocyte-directed actions that regulate leukocyte trafficking to the site of inflammation (4, 8, 10, 18), promoting the uptake and killing of bacteria and enhancing the clearance of apoptotic cells and cellular debris. Results from the present studies demonstrate that knockdown of GPR101 limited the ability of human macrophages to take up both apoptotic cells and bacteria in response to RvD5 n-3 DPA. Furthermore, inhibition of the receptor on human neutrophils using an anti-GPR101 antibody limited the biological actions of RvD5 n-3 DPA thereby reducing the ability of this mediator to promote the uptake and killing of bacteria, reversing its antimicrobial actions on neutrophils, and limiting its ability to reduce neutrophil diapedesis.

Rheumatoid arthritis is an autoimmune disease perpetuated by unremitting joint inflammation that results in bone destruction and joint deformation (29). Neutrophils and monocytes are implicated in the propagation of the effector phase of the disease. In a recent study by our group, we found that, in addition to joint inflammation, inflammatory arthritis also led to gut inflammation and weakening of the gut barrier, an observation that was linked with a reduction in intestinal levels of RvD5 n-3 DPA (11). Furthermore, administration of RvD5 n-3 DPA to arthritic mice reduced both joint and gut inflammation, restoring barrier function and reducing leukocyte infiltration into the paws (9). Here, we report that knockdown of GPR101 limited the protective actions of RvD5 n-3 DPA in reducing joint and intestinal inflammation in experimental inflammatory arthritis. Knockdown of this receptor also blunted the ability of RvD5 n-3 DPA to reduce the levels of inflammatory eicosanoids in the gut and joints of arthritic mice as well as promote the upregulation of SPMs in arthritic mice.

Bacterial infections result from an inability of the host immune response to contain invading pathogens (1). The prevailing approach to treating infections is to inhibit bacterial replication using antibiotics. The recent rise in antibiotic-resistant bacteria has spurred the search for novel approaches to treat infections. Studies investigating endogenous mechanisms promoting the resolution of bacterial infections demonstrate that SPMs reprogram the host immune response to positively regulate the uptake and killing of bacteria (4). Indeed, we found here that RvD5 n-3 DPA promoted the uptake of bacteria by neutrophils, monocytes, and macrophages in a GPR101-dependent manner. Administration of RvD5 n-3 DPA to mice also reduced the exudate concentrations of inflammatory eicosanoids, neutrophil infiltration into the site of inflammation, and the resolution interval from 26 hours to 16 hours. Of note, knockdown of GPR101 reversed these protective actions, underscoring the role of SPMs in reprogramming host immune responses during infection and the role of GPR101 in mediating the immunomodulatory actions of RvD5 n-3 DPA during infections.

In summary, we have identified an immunoregulatory axis centered on GPR101/RvD5 n-3 DPA, that promotes the termination of both sterile and infectious inflammation. These findings demonstrate that GPR101 is the conveyor for the immune-regulatory properties of RvD5 n-3 DPA and establish a role for this receptor in mediating the regulation of joint inflammation, both locally and remotely through the gut barrier, and in instructing the host to efficiently dispose of bacterial pathogens. Thus, these results provide new cues for harnessing the immune-modulatory actions of pro-resolving mediators by developing innovative therapeutic approaches based on the RvD5 n-3 DPA/GPR101 axis.

Methods

**GPCR screening**

Using PathHunter β-arrestin enzyme fragment complementation (EFC) technology coupled with β-gal (DiscoveRx), we screened 49 orphan receptors. GPCR screening was performed by incubating 10 nM RvD5 n-3 DPA or vehicle control (PBS in 0.01% ethanol) at 37°C for 90 minutes with the candidate GPCRs, and receptor activation was determined by measuring the luminescence signal. Negative controls were used to measure the potential constitutive activity in the absence of ligand. This custom screening was performed in duplicate, and the mean chemiluminescence value was used for analysis. The percentage of activity was calculated using the following formula: percentage of activity = 100% × (mean relative luminescence units [RLU] of the test sample – mean RLU of the vehicle control)/(mean RLU of the vehicle control).

**GPCR–β-arrestin assays**

To monitor downstream receptor activation, the β-arrestin PathHunter system (DiscoveRx) was used. CHO cells stably express-
ing human recombinant GPR12, GPR84, or GPR101 coupled to a β-arrestin reporter system were cultured in media containing 10% heat-inactivated FBS. GPCR and β-arrestin expression was maintained by dual selection in hygromycin B and genetin according to the manufacturer’s instructions (DiscoveRx). For the experiments, single-use (xExpress) CHO cells stably expressing human recombinant GPR18 or GPR32 coupled to a β-arrestin reporter system were used. For all GPCR-β-arrestin assays, cells were plated in 96-well plates for 48 hours before experiments using AssayComplete Cell Plating Reagent (DiscoveRx). Cells were incubated with the indicated concentrations of RvD5_0.5 DPA (Vinresol, custom synthesis), PDI_1 DPA or RvDI_1 DPA (provided by Trond Vidar Hansen, University of Oslo, Oslo, Norway) for 1 hour at 37°C, and receptor activation was determined by measuring chemiluminescence using the PathHunter Detection Kit (DiscoveRx).

**xCELLigence RTCA DP system**

Ligand-receptor interactions were assessed by monitoring impedance changes across single-cell monolayers using an xCELLigence DP System (ACEA Biosciences). GPR101-overexpressing CHO cells were plated on electronic microtiter plates (E-Plates). Test compounds were added to the chambers in serum-free medium, and real-time impedance changes were monitored (0–30 minutes at 37°C). For antibody incubations, anti-GPR101 antibody (clone G278, host: rabbit, Assay Biotechnology) or nonimmune rabbit IgG was incubated with cells on microtiter plates at 1:50 dilutions for 20 minutes before addition of the indicated mediators. In select experiments, GPR101-overexpressing CHO cells were incubated with CTX (1 μg/mL, 2 hours), PTX (1 μg/mL, 16 hours), or vehicle. Cells were then washed with serum-free HAM F-12 serum-free medium. RvD5_0.5 DPA (10 nM) was added and impedance changes were assessed over a 30-minute period.

**Preparation of [10, 11, 13, 14]H-RvD5_0.5 DPA and radioligand binding**

Total organic synthesis of [10, 11, 13,14H]-RvD5_0.5 DPA was done by Vinresol (custom synthesis) via the tritiation of (7S,8E,15E,17S,19Z)-7,17-dihydroxydocosahexa-8,15,19-trien-10,13-diynoate. The integrity and activity of the radioligand was ascertained using reverse-phase UV-HPLC (RV-UV-HPLC) system (1100 Series, Agilent Technologies) equipped with an Eclipse Plus C18 Column (100 mm × 4.6 mm × 1.8 μm; Agilent Technologies) coupled with a diode array detector (DAD) (G1315B; Agilent Technologies). A gradient of methanol/water of 55:45 (vol/vol) was ramped to 63:37 (vol/vol) over a 22-minute period and then to 98:2 (vol/vol) for the next 8 minutes. The flow rate was maintained at 0.5 mL/min.

To assess the affinity of the radioligand for human GPR101, GPR101-overexpressing CHO cells were suspended in DPBS containing Ca²⁺ and Mg²⁺. For competition binding experiments, 0.5 × 10⁵ cells/0.1 mL were incubated with approximately 3 nM [10, 11, 13,14H]-RvD5_0.5 DPA (specific activity ~40 Ci/mmol) in the absence or presence of increasing concentrations of unlabeled RvD5_0.5 DPA (1 nM–10 μM). Following incubation for 60 minutes at 4°C, cells were transferred to Whatman GF/C glass microfiber filters (Thermo Fisher Scientific), and unbound ligand was removed by washing twice with 4 mL ice-cold Dulbecco’s PBS (DPBS) using a vacuum manifold (MilliporeSigma). Bound radioactivity was then determined using a scintillation counter (Beckman Coulter). Nonspecific binding was determined in the presence of 10 μM unlabeled RvD5_0.5 DPA.

For saturation binding experiments, 0.5 × 10⁵ cells/0.1 mL cells were incubated with [10, 11, 13,14H]-RvD5_0.5 DPA (1.25-100 nM), and then with or without 10 μM RvD5_0.5 DPA for 60 minutes at 4°C. Cells were then transferred onto Whatman GF/C glass microfiber filters, and unbound ligand was removed by washing twice with 4 mL ice-cold DPBS using a vacuum manifold (MilliporeSigma). Bound radioactivity was determined using a scintillation counter (Beckman Coulter).

**GPCR expression on primary cells**

**Human leukocyte GPCR expression.** Expression of GPR101, GPR12 (host: rabbit, lot AG1102912, catalog bs-13514R, Bioss) and GPR84 (host: mouse, lot 08248 WECz, catalog HO0053831-A01, Abnova) was assessed in human peripheral blood monocytes, neutrophils, and macrophages. Nonspecific binding was quenched using FC blocking solution. Human leukocytes were incubated with antibody–human GPR101, rabbit anti-human GPR12, or mouse anti-human GPR84 (30 minutes at 4°C) and then with AF488-conjugated goat anti-rabbit IgG (Thermo Fisher Scientific) or AF488-conjugated goat anti-mouse IgG (Thermo Fisher Scientific) for 30 minutes at 4°C. Cells were then incubated with AF647-conjugated anti-human CD14 (clone HCD14, BioLegend) and APC-Cy7-conjugated anti–human CD16 (clone 3G8, BioLegend; for monocytes) antibodies (30 minutes at 4°C). For whole blood incubation, RBCs were lysed using a BD Pharmingen Red Blood Cell Lysis Kit following the manufacturer’s instructions, and fluorescence staining was evaluated using an LSR Fortessa Cell Analyzer (BD Biosciences) and FlowJo software, version 10 (Tree Star).

**Mouse leukocyte GPCR expression.** Peripheral blood was collected via cardiac puncture in 3.2% sodium citrate. Cells were then incubated with anti–mouse CD16/CD32 (clone 93, eBioscience; dilution 1:100, 20 minutes at 4°C in PBS containing 5% FCS staining solution). Peripheral blood cells were then incubated with AF700-conjugated anti–mouse Ly6G (clone 1A8, BioLegend; for neutrophils) and BV421-conjugated anti–mouse CD115 (clone AF589, BioLegend; for monocytes) antibodies (30 minutes at 4°C), and receptor expression was evaluated as described above.

**Targeted lipid mediator profiling**

Paws and intestinal tissues were collected and immediately transferred to liquid nitrogen prior to homogenization in 1 mL ice-cold MeOH using a glass dounce. All samples for LC-MS/MS–based profiling were extracted using solid-phase extraction columns as described previously (30). Prior to sample extraction, deuterated internal standards, representing each region in the chromatographic analysis (500 pg each) were added to facilitate quantification. Samples were kept at −20°C for a minimum of 45 minutes to allow for protein precipitation. Supernatants were subjected to solid-phase extraction, and the methyl formate fraction was collected, brought to dryness, and suspended in phase (methanol/water, 1:1, vol/vol) for injection on a Shimadzu LC-20AD HPLC and a Shimadzu SIL-20AC autoinjector, paired with a QTrap 6500 Plus (Sciex). An Agilent Poroshell 120 EC-C18 column (100 mm × 4.6 mm × 2.7 μm) was kept at 50°C and the mediators eluted using a mobile phase consisting of methanol/water/acetic acid ratio of 20:80:0.01 (vol/vol/vol) that was ramped to 50:50:0.01 (vol/vol/vol) over 0.5 minutes and then to 80:20:0.01 (vol/vol/vol) from 2 minutes to 11 minutes, maintained until 14.5 minutes, and then rapidly ramped to 98:2:0.01 (vol/vol/vol) for the next 0.1 minutes. This was subsequently maintained at 98:2:0.01 (vol/vol/vol) for 5.4 minutes, and the flow rate was maintained at 0.5 mL/min. QTrap 6500 Plus was operated using a multiple reaction monitoring method as previ-
ously described (30). Each lipid mediator was identified using established criteria including matching of the retention time to synthetic or authentic standards and at least 6 diagnostic ions (30). Calibration curves were obtained for each mediator using lipid mediator mixtures at 0.78, 1.56, 3.12, 6.25, 12.5, 25, 50, 100, and 200 pg that gave linear calibration curves with $r^2$ values of 0.98–0.99.

Animal experiments

*E. coli peritonitis.* Six- to eight-week-old male C57BL/6 mice (Charles River Laboratories, the supplier fed the mice a lab diet containing essential fatty acids) were administered 9 μg Accell Control siRNA or Accell Mouse GPR101 siRNA SMARTPool (Dharmacon) via i.p. injection. After 3 days, mice were administered RvD5<sub>n-3</sub> DPA (100 ng/mouse) or vehicle via i.p. injection immediately prior to i.p. injection of live *E. coli* (serotype O6:K2:H1, 10<sup>8</sup> CFU per mouse). At designated time intervals, the mice were euthanized, blood was collected via cardiac puncture in sodium citrate, and peritoneal exudates were collected in 4 mL PBS.

The cellular composition in the exudates was determined using Turk’s solution, light microscopy, and flow cytometry. For the latter, exudate cells were incubated with anti-mouse CD16/CD32 (clone 93, eBioscience; dilution 1:100, 20 minutes at 4°C in PBS containing 5% FCS staining solution), followed by incubation with phycoerythrin (PE) conjugated anti–mouse Ly6G antibody (clone 1A8, BioLegend; for neutrophils), Alexa Fluor 700 Ly-6G (clone IA1, host rat, BioLegend), Brilliant Violet 711 CD115 (CSF-1R) (clone AF598, host rat, BioLegend), Brilliant Violet 510 CD43 (clone 1G10, host mouse, BD Biosciences), and APC/cyanine7 F4/80 (clone BM8, host rat, BioLegend) for 45 minutes on ice. To assess bacterial phagocytosis in peritoneal exudate leukocytes, exudate cells were incubated with anti-mouse CD16/CD32 (clone 93, eBioscience; dilution 1:100, 20 minutes at 4°C in PBS containing 5% FCS staining solution) and then with Alexa Fluor 700–conjugated anti-mouse Ly6G (for neutrophils), APC/Cy7-conjugated anti-mouse F4/80, and PE-conjugated anti-mouse CD64 antibodies (monocyte-derived macrophages; 30 minutes at 4°C in staining solution). Cells were then fixed and permeabilized using BD Perm/Wash Buffer (BD Biosciences) following the manufacturer’s instructions and incubated with FITC-conjugated anti–E. coli antibody (catalog GTX13626, GenTex; 1:50 dilution, 30 minutes at 4°C in BD Perm/Wash Buffer).

We assessed efferocytosis in infectious exudates by incubating exudate leukocytes with anti-mouse CD16 and anti-mouse CD32 and then with APC- and Cy7-conjugated anti-mouse F4/80 and PE-conjugated anti-mouse CD64 antibodies (30 minutes at 4°C in staining solution). Cells were then fixed and permeabilized using BD Perm/Wash Buffer (BD Biosciences) and incubated with FITC-conjugated anti-mouse Ly6G antibody (30 minutes at 4°C, in BD Perm/Wash Buffer).

In select experiments, resolution indices were calculated as described previously (17, 18), where the time difference for neutrophil numbers to go from maximum to half maximum was determined as the R<sub>T</sub>. To assess the pro-resolving actions of the test products, these products were administered 12 hours after *E. coli* (10<sup>8</sup> CFU) inoculation, and resolution indices were assessed.

**Inflammatory arthritis.** Ten-week-old male C57BL/6 mice (Charles River Laboratories, the supplier fed the mice a lab diet containing essential fatty acids) were administered 9 μg Accell Control siRNA or Accell Mouse GPR101 siRNA SmartPool (Dharmacon) via i.p. injection. After 24 hours, mice were i.p. administered 100 μl K/BxN serum (provided by Mauro Perretti and Dianne Cooper, Queen Mary University of London, London, United Kingdom) on days 0 and 2 to initiate inflammatory arthritis. Clinical scores were monitored daily using a 26-point arthritic scoring system (11). Mouse ankles, wrists, pads, and digits were inspected daily for swelling and redness. Blood, paws, and intestines were collected on day 8.

*Mouse peripheral blood leukocyte phagocytosis.* Six- to eight-week-old male C57BL/6 mice (Charles River Laboratories; the supplier fed the mice a lab diet containing essential fatty acids) were i.p. administered 8 μg Accell Control siRNA or Accell Mouse GPR101 siRNA SMARTPool (Dharmacon). After 3 days, blood was collected via cardiac puncture and incubated with either RvD5<sub>n-3</sub> DPA (10 nM) or vehicle (PBS containing 0.1% ethanol) for 20 minutes at 37°C, and then with 5 × 10<sup>6</sup> CFU fluorescently labeled *E. coli* for 60 minutes at 37°C. At the end of the incubations, RBCs were lysed using a BD Pharmingen Red Blood Cell Lysis Kit following the manufacturer’s instructions. The cells were then fixed and incubated with anti-CD16/CD32 antibody (20 minutes at 4°C) followed by AF700-conjugated anti-mouse Ly6G (clone IA8, BioLegend; for neutrophils) and BV-421-conjugated anti-mouse CD115 (clone AF598, BioLegend; for monocytes) antibodies (30 minutes at 4°C). Cells were then washed and staining evaluated using a BD Fortessa II with BD FACSDiva software, and the results were analyzed using FlowJo software, version 10.4 (Tree Star).

**Blood collection from healthy volunteers**

Venous peripheral blood was collected at the indicated intervals in sodium citrate (3.2%) from fasting volunteers who declared they had not taken NSAIDS for at least 14 days or consumed caffeine or alcohol for at least 24 hours or fatty fish for at least 48 hours.

**Human neutrophil responses**

*Human neutrophil chemotaxis.* Human peripheral blood neutrophils were isolated from healthy volunteers as detailed above. Cells were incubated with either an antibody against GPR101 or an isotype control for 15 minutes at room temperature and then with RvD5<sub>n-3</sub> DPA (0.1–10 nM) or vehicle control (PBS containing 0.01% ethanol) for 15 minutes at 37°C. Neutrophils were then transferred to the top chamber of a preloaded cell invasion and migration plate (CIM-Plate 16) on an xCELLigence DP system, and chemotaxis toward LTB<sub>4</sub> (10 nM) was assessed in real time for 30 minutes.

*Human neutrophil-endothelial cell interactions.* Human neutrophils, isolated as detailed above, were incubated with either an antibody against GPR101 or an isotype control for 15 minutes at room temperature and then with RvD5<sub>n-3</sub> DPA (0.1–10 nM) or vehicle control (PBS containing 0.01% ethanol) for 15 minutes at 37°C. Cells were then perfused over TNF-α-activated human umbilical endothelial cells (10 ng/mL, 4 hours) at 0.1 PA for 8 minutes, 6 random 10-second fields were recorded per condition, and neutrophil–endothelial cell interactions were quantified as previously described (4).

**Human macrophage responses**

*Human monocyte-derived macrophage efferocytosis.* PBMCs from healthy volunteers were purchased from the NHS Blood and Transplant Bank. PBMCs were isolated using Histopaque 1077 (MilliporeSigma) density centrifugation from blood cones. Macrophages were prepared using previously published protocols (31). Briefly, PBMCs were plated onto
on day 7, monocyte-derived macrophages were then seeded onto 96-well plates at 4 × 10^4 cells per well and transfected with 1 μM Accell Human Control siRNA or Accell Anti–human GPR101 siRNA SMARTpool for 72 hours in serum-free Accell siRNA Delivery Medium (Dharmacon). Apoptotic target cells for efferocytosis were generated as follows: human promyelocytic HL-60 cells were seeded at 1 × 10^6 cells/mL onto 35-mm plates, illuminated with UV-C light (254 nm) for 15 minutes, and incubated at 37°C for 2 hours. Apoptosis induction was verified by flow cytometry using the APC Annexin V Apoptosis Detection Kit with PI (BioLegend), in which annexin V–positive and annexin V/PI–double-positive cells were considered to be apoptotic. Apoptotic HL-60 cells were washed with PBS and labeled with 1 μM pHrodo Red Succhinimidyl Ester (Invitrogen, Thermo Fisher Scientific) in PBS for 30 minutes at room temperature. Macrophages were stained with CellBrite Blue (Biotium) for 1 hour at 37°C to visualize cell membranes, washed with RPMI-1640, and incubated with RvD5_{n-3 DPA} (0.001–10 nM) or vehicle (RPMI-1640 containing 0.1% ethanol) for 15 minutes at 37°C. Apoptotic pHrodo Red-labeled HL-60 cells were added directly to the macrophages at a 3:1 ratio (apoptotic HL-60 macrophage), and the increase in pHrodo Red signal over time (representing apoptotic cell efferocytosis by macrophages) was quantified using a Zeiss CellDiscoverer 7 high-content imaging system.

**Human monocyte–derived macrophage phagocytosis**. Monocyte-derived macrophages were seeded onto 96-well plates at 4 × 10^4 cells per well and transfected with 1 μM Accell Human Control siRNA or Accell Anti–human GPR101 siRNA SMARTpool for 72 hours in serum-free Accell siRNA Delivery Medium (Dharmacon). Macrophages were stained with Hoechst 33342 (Thermo Fisher Scientific) for 1 hour at 37°C to visualize cell nuclei, washed with RPMI-1640, and incubated with RvD5_{n-3 DPA} (0.001–10 nM) or vehicle (RPMI-1640 containing 0.1% ethanol) for 15 minutes at 37°C. pHrodo Green–labeled S. aureus bioparticle conjugates (Invitrogen, Thermo Fisher Scientific) were opsonized by incubation in PBS containing 20% (v/v) human serum. Opsonized pHrodo Green-labeled S. aureus bioparticles were directly added to the macrophages at a final concentration of 5 μg per well, and the increase in pHrodo Green signal over time (representing bacterial particle by macrophages) was quantified using a Zeiss CellDiscoverer 7 high-content imaging system.

**cAMP measurements**. Human monocyte–derived macrophages were seeded onto 12-well plates at 5 × 10^5 cells per well and then transfected with 1 μM Accell Human Control siRNA or Accell Anti–human GPR101 siRNA SMARTpool for 72 hours in serum-free Accell siRNA Delivery Medium (Dharmacon). Cells were incubated with RvD5_{n-3 DPA} (1 nM) or vehicle (PBS containing 0.01% ethanol) for 2 minutes, after which incubations were quenched with 5% Triton X-100, cells were homogenized, and cAMP levels were determined using an ELISA following the manufacturer’s instruction (Elite cAMP ELISA Assay kit, eEnzyme).}

Address correspondence to: Jesmond Dalli, Lipid Mediator Unit, William Harvey Research Institute, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, United Kingdom. Phone: 44.207.882.8263; Email: j.dalli@qmul.ac.uk.
1. Majno G. The ancient riddle of sigma eta psi iota sigma (sepsis). J Infect Dis. 1991;163(5):937–945.

2. Malagoli D. The evolution of the immune system: conservation and diversification. Cambridge, Massachusetts, USA: Academic Press; 2016.

3. Scapini P, Cassatella MA. Location in the spleen dictates the function of murine neutrophils. J Exp Med. 2017;214(5):1207–1209.

4. Spite M, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009;461(7268):1287–1291.

5. Quiros M, et al. Macrophage-derived IL-10 mediates mucosal repair by epithelial WISP-1 signaling. J Clin Invest. 2017;127(9):3510–3520.

6. Sumagin R, et al. Neutrophil interactions with epithelial-expressed ICAM-1 enhances intestinal mucosal wound healing. Mucosal Immunol. 2016;9(5):1151–1162.

7. Dalli J, Serhan CN. Pro-resolving mediators in regulating and conferring macrophage function. Front Immunol. 2017;8:1400.

8. Hellmann J, et al. Biosynthesis of D-series resolvins in skin provides insights into their role in tissue repair. J Invest Dermatol. 2018;138(9):2051–2060.

9. Colas RA, et al. Impaired production and diurnal regulation of vascular RvD1 n-3 DPA increase systemic inflammation and cardiovascular disease. Circ Res. 2018;122(9):855–863.

10. Dalli J, Colas RA, Serhan CN. Novel n-3 immunoresolvons: structures and actions. Sci Rep. 2013;3:1940.

11. Flak MB, Colas RA, Muñoz-Arrieta E, Curtis MA, Dalli J, Pitzalis C. Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis. JCI Insight. 2019;4(13):125191.

12. Dalli J, Serhan CN. Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology. Br J Pharmacol. 2019;176(8):1024–1037.

13. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282(16):11613–11617.

14. Fiore S, Romano M, Reardon EM, Serhan CN. Induction of functional lipoxin A4 receptors in HL-60 cells. Blood. 1993;81(12):3395–3403.

15. Perretti M, et al. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med. 2002;8(11):1296–1302.

16. Krishnamoorthy S, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci USA. 2010;107(4):1660–1665.

17. Dalli J, et al. Resolvin D3 and aspirin-triggered resolvin D5 are potent immunoresolvents. Chem Biol. 2013;20(2):188–201.

18. Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. J Exp Med. 2015;212(9):1203–1217.

19. Olson KR, Eglen RM. Beta galactosidase complementation: a cell-based lumincent assay platform for drug discovery. Assay Drug Dev Technol. 2007;5(1):137–144.

20. Peters MF, Scott CW. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen. 2009;14(3):246–255.

21. Gerlach BD, et al. Resolvin D1 promotes the targeting and clearance of necroptotic cells [published online ahead of print June 20, 2019]. Cell Death Differ. https://doi.org/10.1038/ s41418-019-0370-1.